Lifestyle therapy, no medication yet: this MN566 Unit 9 paper defends that choice for composite stage 1 hypertension against the exact ACC/AHA recommendation and risk threshold behind it. Searches like "mn 566 unit 9 assignment example", "mn566 unit 9 sample" and "mn566 unit 9 example" land here.
Lifestyle Therapy Alone for Stage 1 Hypertension at a 6.8 Percent Ten-Year Risk: Applying the 2017 ACC/AHA Guideline
[Student Name]
Purdue University Global
MN566: NP I - Introduction to Primary Care for the Nurse Practitioner
Unit 9 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. The guideline edition checked is named in the conclusion; nothing here is a prescribing instruction.
Introduction
Should this patient start an antihypertensive now? The answer defended here is no. A composite 54-year-old accountant has stage 1 hypertension confirmed outside the office, no diabetes, no chronic kidney disease and no cardiovascular disease, and a calculated 10-year risk of atherosclerotic cardiovascular disease of 6.8 percent. Under the 2017 ACC/AHA guideline, a patient with these features should begin nonpharmacologic therapy and have his blood pressure reassessed in three to six months, with medication reserved for higher readings or higher risk (Whelton et al., 2018). The rest of the paper supports that claim.
The Case
Only the data the decision requires are given here.
Blood pressure. Office readings averaged 136/86 across two visits, each the average of two seated readings taken with a validated device and correct cuff. Home readings averaged 134/84 over seven days, measured twice each morning and evening after five minutes of rest.
Conditions that would change the threshold. No diabetes: A1C 5.4 percent. No chronic kidney disease: estimated glomerular filtration rate 92 and no albuminuria. No known cardiovascular disease.
Risk estimate. Total cholesterol 198 mg/dL, HDL 48 mg/dL, nonsmoker, not on treatment for blood pressure. The Pooled Cohort Equations, using his age, sex, race, cholesterol, HDL, systolic pressure, diabetes status and smoking status, give a 10-year risk of 6.8 percent (Goff et al., 2014).
Other history, including a knee replacement and seasonal allergies, does not bear on the decision and is left out.
The Guideline and the Match
The 2017 ACC/AHA guideline defines stage 1 hypertension as systolic pressure of 130 to 139 mm Hg or diastolic pressure of 80 to 89 mm Hg (Whelton et al., 2018). His office and home averages both fall in that range on both numbers. He has stage 1 hypertension.
The guideline then separates stage 1 patients by risk. For adults with stage 1 hypertension whose estimated ten-year risk reaches 10 percent, or who have clinical cardiovascular disease, it recommends medication together with lifestyle change. For adults whose 10-year risk is below 10 percent, it recommends nonpharmacologic therapy with reassessment of blood pressure in three to six months. In the same guideline, medication for primary prevention in adults with a risk below 10 percent is a Class I recommendation only when systolic pressure is 140 mm Hg or higher or diastolic pressure is 90 mm Hg or higher.
Each condition is now checked against the case:
Stage 1 hypertension: met, 136/86 in the office and 134/84 at home.
No clinical cardiovascular disease: met.
10-year risk below 10 percent: met, 6.8 percent.
Readings below 140/90: met on both numbers.
Every condition for nonpharmacologic therapy alone is met, and none of the conditions for medication is. Diabetes and chronic kidney disease are checked specifically because the guideline treats those conditions as placing patients at higher risk; he has neither.
Confirming the Readings Outside the Clinic
The decision depends on the diagnosis being right. The US Preventive Services Task Force recommends obtaining blood pressure measurements outside the clinical setting to confirm the diagnosis before starting treatment, because office readings alone can misclassify people with white coat hypertension (US Preventive Services Task Force, 2021). His home average of 134/84 agrees with his office average, so the diagnosis of stage 1 hypertension is confirmed rather than an artifact of the clinic.
Why the Guidelines Disagree
The 2014 report of the panel appointed to the eighth Joint National Committee used 140/90 as the threshold for starting medication in adults under 60 (James et al., 2014). Under that report he would not be called hypertensive in the sense that triggers treatment, and he would receive no medication. The two documents reach the same practical answer for him, but by different routes, and the difference in their thresholds is not arbitrary.
JNC 8 was built on randomized trials of drug treatment and set thresholds where trials had shown benefit from medication. It asked, in effect, at what level do drugs help. The 2017 ACC/AHA guideline drew on observational data showing that cardiovascular risk rises steadily from pressures well below 140/90, and on trials in higher-risk patients. It asked at what level risk begins, and it lowered the threshold for diagnosis while tying the threshold for medication to overall risk. For a low-risk patient at 136/86, the newer guideline gives him a diagnosis and a lifestyle plan, while the older one would give him reassurance. The newer approach has the advantage of starting lifestyle change earlier, when it may prevent progression. Its cost is that more people carry a diagnosis, and some may feel labeled by a number that would not have concerned an earlier generation of clinicians; that cost is why the plan is presented to him as a chance to act early rather than as a disease.
The Plan
The recommendation becomes specific actions:
Diet: a DASH-style eating plan, with a referral to a dietitian and sodium reduced toward 1,500 mg a day.
Activity: 90 to 150 minutes a week of aerobic exercise; he plans brisk walking at lunch five days a week.
Weight: a goal of losing 3 to 4 kg over six months, since his BMI is 27.
Alcohol: he drinks four beers a week, within the guideline's limit for men, and no change is needed.
Home monitoring: readings twice a day for one week before the next visit.
Reassessment: a visit in four months, on [date], with his home log and a repeat risk estimate.
What Would Reverse the Decision
Two results would change the answer. A recalculated ten-year estimate at or above the 10 percent line, which could occur if his cholesterol rises or if diabetes develops, would move him into the group for whom medication is recommended at stage 1. Readings averaging 140/90 or higher at home or in the office would place him in stage 2, where medication is recommended regardless of risk. Either would prompt a discussion of starting a first-line agent at the next visit.
Conclusion
For this patient, lifestyle therapy alone is the guideline-concordant choice, and the plan has a date on which it will be tested. The 2017 ACC/AHA guideline, published in 2018 in Hypertension, was the edition checked for this paper; if a newer edition has been issued by the time of his reassessment, the thresholds should be checked against it before the decision is repeated.
References
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D'Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O'Donnell, C. J., Robinson, J. G., Schwartz, J. S., Shero, S. T., Smith, S. C., Sorlie, P., Stone, N. J., & Wilson, P. W. F. (2014). 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 129(25 Suppl. 2), S49-S73. https://doi.org/10.1161/01.cir.0000437741.48606.98
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., Smith, S. C., Svetkey, L. P., Taler, S. J., Townsend, R. R., Wright, J. T., Narva, A. S., & Ortiz, E. (2014). 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA, 311(5), 507-520. https://doi.org/10.1001/jama.2013.284427
US Preventive Services Task Force. (2021). Screening for hypertension in adults: US Preventive Services Task Force reaffirmation recommendation statement. JAMA, 325(16), 1650-1656. https://doi.org/10.1001/jama.2021.4987
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., ... Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
How this MN566 Unit 9 example is structured
The paper is built as an argument with a single claim. Its introduction poses the question and states the answer, so the rest reads as support. The case section presents only the data the recommendation requires, which is why out-of-office confirmation, diabetes and kidney status, and the risk estimate appear while unrelated history does not. The guideline section quotes the recommendation, names its class and level of evidence, and shows the case meeting each condition. A short paragraph on confirming readings outside the clinic cites the 2021 USPSTF hypertension screening statement. The comparison with JNC 8 explains why guidelines disagree rather than noting that they do. The plan turns the recommendation into specific actions and a date. Finally, the paper names what would reverse the decision, a recalculated risk of 10 percent or more or stage 2 readings, and which edition was checked.
Get an MN566 Unit 9 example written to your instructions
Share the Unit 9 case and the guideline your MN566 section names, or the management question if you choose it yourself, plus the rubric. You get a first paper free within 24-48h, quoting the exact recommendation, matching each of its conditions to the composite case, and naming what finding would reverse the decision. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
MN566 Unit 9 questions, answered
Which guideline should the paper apply?
Whichever your prompt specifies, or the current national guideline for the condition if the choice is yours. For blood pressure in the United States, the ACC/AHA guideline is the usual reference, with JNC 8 useful as a contrast. Confirm the edition before drafting, because thresholds and risk tools change, and cite the recommendation itself rather than a summary of it.
Is it acceptable to depart from the guideline?
Yes, if the paper explains why this patient falls outside the evidence behind the recommendation. Guidelines describe populations, and a documented reason to depart from one, such as a comorbidity or a patient preference, can be sound. The paper should state the recommendation, the reason for departing, and what monitoring makes the departure safe.
How much of the paper should describe the disease itself?
Very little. A paragraph of background is usually enough, and some rubrics want none. The paper is graded on how well the recommendation fits the case and how clearly the decision follows from it. Pathophysiology that does not bear on the management choice takes space the application needs, and graders tend to skim past it.